Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger (SDGR) reported strong Q4 and full-year 2024 results, with total software revenue reaching $180.4 million, up 13.3% from 2023. Q4 total revenue increased 19.1% to $88.3 million.

The company's software business showed resilience with total annual contract value increasing 23.7% to $190.8 million. However, full-year drug discovery revenue decreased to $27.2 million from $57.5 million in 2023. The company reported a net loss of $187.1 million for 2024.

Looking ahead to 2025, Schrödinger expects:

• Software revenue growth of 10-15%
• Drug discovery revenue of $45-50 million
• Software gross margin of 74-75%
• Operating expense growth less than 5%

The company expanded collaborations with Eli Lilly and Otsuka, and received a $150 million upfront payment from Novartis in January 2025. Initial Phase 1 data from three proprietary programs is expected in 2025.

Schrödinger (SDGR) has announced its management's participation in three major investor conferences in March 2025. The company will be featured in fireside chat sessions at the following events:

• TD Cowen 45th Annual Health Care Conference on March 4 at 10:30 a.m. ET
• Leerink Partners Global Biopharma Conference on March 10 at 3:40 p.m. ET
• KBCM Healthcare Forum on March 18 at 9:00 a.m. ET

All discussions will be accessible through the Investors section of Schrödinger's website and will remain available for approximately 90 days after each event.

Schrödinger (SDGR) has granted restricted stock units (RSUs) for 5,445 shares of common stock to five newly hired employees on February 17, 2025. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs feature a four-year vesting schedule: 25% vests after 12 months of continuous service from the vesting commencement date, followed by the remaining balance vesting in three equal yearly installments of 25% each. These inducement grants are governed by award agreements and the company's 2021 Inducement Equity Incentive Plan.

Schrödinger (Nasdaq: SDGR) has announced it will release its fourth quarter and full-year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss the results. Investors can access the live webcast through the company's website's 'Investors' section, where it will remain available for approximately 90 days.

Schrödinger (SDGR) has granted restricted stock units (RSUs) for 4,840 shares of common stock to four newly hired employees on January 20, 2025. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs feature a four-year vesting schedule: 25% vests after 12 months of continuous service from the vesting commencement date, followed by the remaining balance vesting in three equal yearly installments of 25% each. These inducement grants are governed by award agreements and the company's 2021 Inducement Equity Incentive Plan.

Schrödinger provided an update on its 2024 progress and outlined its 2025 strategic priorities. Key highlights include:

Expanded Collaborations: Schrödinger expanded its research collaboration with Otsuka Pharmaceutical Co., , and its agreement with Novartis, which includes a $150 million upfront payment expected in Q1 2025.

2024 Achievements: The company launched initiatives to enhance its computational platform and introduced LiveDesign Biologics. It published 29 peer-reviewed articles and advanced Phase 1 clinical studies for SGR-1505, SGR-2921, and SGR-3515. The FDA granted Fast Track Designation to SGR-2921.

Collaborations and Investments: Schrödinger announced a $150 million collaboration with Novartis, with potential milestone payments of up to $2.3 billion. Co-founded companies, including Morphic Holding and Ajax Therapeutics, made significant progress in their respective fields.

2025 Strategic Priorities: Schrödinger aims to increase customer adoption of its technology, advance predictive toxicology, and present initial Phase 1 data for SGR-1505, SGR-2921, and SGR-3515.

Schrödinger will release its Q4 and full-year financial results on February 26, 2025.

Schrödinger (SDGR) has granted restricted stock units (RSUs) for 8,365 shares to six newly hired employees on December 12, 2024. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee. The RSUs will vest over four years, with 25% vesting after 12 months of continuous service, followed by equal yearly installments of 25% over the next three years. These grants serve as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).

Schrödinger (Nasdaq: SDGR) has announced its upcoming participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, December 4, 2024, at 8:30 a.m. ET. Interested parties can access the live webcast through the 'Investors' section of Schrödinger's website, where it will remain available for approximately 90 days after the event.

Schrödinger (SDGR) has granted restricted stock units (RSUs) for 2,785 shares to four new employees as inducement awards. The grants, made under the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs follow a four-year vesting schedule, with 25% vesting after 12 months of continuous service and the remaining 75% vesting in equal yearly installments over the following three years.